P.1.091 Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial

The Cost-effectiveness of Lamotrigine in the Maintenance Treatment of Adults With Bipolar I Disorder

“…These findings are the result of an indirect comparison using outcomes from the Bowden 13 and the Tohen 15,16 trials. In the absence of head-to-head trial data, it is legitimate practice in economic evaluations to use modeling techniques to make indirect comparisons (as frequently demonstrated by NICE and the SMC in the United Kingdom).…”

“…15 This research has recently been published. 16 The olanzapine study used similar patients and outcome measures to the Bowden trial (bipolar patients with a recent manic episode).…”

“…As discussed above, a supplementary economic evaluation of olanzapine monotherapy (using an average dose of 12.5 mg Had a diagnosis of bipolar I disorder, most recent episode manic or hypomanic as determined by DSM-IV, or had a manic/hypomanic episode either currently or within 60 days prior to screening, and had at least 1 manic/ hypomanic episode and 1 depression episode within the previous 3 years per day, derived from using outcome data from results presented by Tohen 15,16 ), was added during the course of our research.…”

“…The trials recorded the time to intervention for the first event 13 and Tohen et al 15,16 Resource Use Assumptions and Sources (manic, hypomanic, mixed, or depressive episode) and the number of patients completing the 18 months free of intervention for an actual or emerging mood episode (completers). These event probabilities were used to derive the quarterly transitional probabilities used in the model.…”

“…We derived transitional probabilities for olanzapine using Tohen' s 15 reported outcomes and anchoring to Bowden outcomes using the placebo results from these 2 trials. In brief, we estimated the risks ratios of modeled events for patients receiving olanzapine compared with the placebo group.…”